Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled Phase 3 study of migalastat (AT1001) in Fabry disease with AT1001-responsive GLA mutations
2009-013459-31Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Sep 2009
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing Migalastat with Placebo (2 arms). Primary endpoint: Kidney GL-3 (interstitial capillary histology). Started Sep 2009; status: completed.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2009-013459-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013459-31.